AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18992700
Drug: Levodopa medication
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa medication withdrawal (experimental group)
Trial: 18992700
Drug: Continued levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continued levodopa medication (control group)
Trial: 15877999
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg/day for 4 months)
Trial: 12373663
Drug: Levetiracetam (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (1,000 to 4,000 mg)
Trial: 2205544
Drug: Ophthalmic rod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic rod (OR) with tropicamide
Trial: 2205544
Drug: Ophthalmic rod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic rod (OR) with oxybuprocaine HCl
Trial: 2205544
Drug: Ophthalmic rod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic rod (OR) with fluorescein sodium
Trial: 6507951
Drug: methylprednisolone 125
RxNorm normalized name: methylprednisolone 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone 125 mg every 6 hours
Trial: 6507951
Drug: methylprednisolone 60
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylprednisolone 60 mg every 6 hours
Trial: 6507951
Drug: hydrocortisone 100
RxNorm normalized name: hydrocortisone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrocortisone 100 mg every 6 hours
Trial: 6507951
Drug: higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: higher dose glucocorticoid therapy
Trial: 18801505
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg degarelix followed by monthly injections of 60 mg
Trial: 18801505
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg degarelix followed by monthly injections of 80 mg
Trial: 18538469
Drug: Degarelix treatment
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix treatment
Trial: 15695129
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg plus fenofibrate 160 mg (combination therapy)
Trial: 12061948
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (5 grams daily)
Trial: 7023861
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate (0.05 mg/kg)
Trial: 2135208
Drug: Indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75 mg oral dose)
Trial: 25122422
Drug: IHC (Immunohistochemistry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IHC (Immunohistochemistry) using 5A4, ALK1, or D5F3 antibodies; optimized protocols were used after initial results.
Trial: 22266899
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.2% ropivacaine at 4 mL/hr for 48 hours
Trial: 22266899
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.2% ropivacaine
Trial: 15724724
Drug: PspA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PspA vaccine
Trial: 3478996
Drug: Aspirin 20
RxNorm normalized name: aspirin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 20 mg
Trial: 26988693
Drug: Probiotics (multi-strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (multi-strain microbial cell preparation)
Trial: 16409564
Drug: Tablet dispenser
RxNorm normalized name: Camrese 13 Week Extended-Day Tablet Dispenser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet dispenser (TD)
Trial: 8829027
Drug: ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (8 mg BID for up to 3 days)
Trial: 8829027
Drug: prochlorperazine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prochlorperazine (10 mg BID for up to 3 days)
Trial: 2413835
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose PVB (cis-platinum 20 mg/m2 days 1-5 every 3 weeks for four courses, bleomycin 30 mg weekly for 12 weeks, vinblastine 0.20 mg/kg on days 1 and 2 every 3 weeks for four courses)
Trial: 2413835
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose PVB (cis-platinum 20 mg/m2 days 1-5 every 3 weeks for four courses, bleomycin 30 mg weekly for 12 weeks, vinblastine 0.15 mg/kg on days 1 and 2 every 3 weeks for four courses)
Trial: 2413835
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (cis-platinum and vinblastine for 1 year)
Trial: 24108668
Drug: Everolimus (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (30, 50, or 70 mg)
Trial: 24108668
Drug: Cetuximab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (400 mg/m(2) loading, 250 mg/m(2) maintenance)
Trial: 19915181
Drug: Loxapine aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxapine aerosol (0.625, 1.25, 2.5, 5.0, or 10 mg)
Trial: 9841829
Drug: Oral, killed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, killed enterotoxigenic Escherichia coli (ETEC) plus cholera toxin B subunit vaccine
Trial: 1347204
Drug: Vecuronium 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.015 mg.kg-1
Trial: 3922823
Drug: terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 60 mg twice a day
Trial: 3922823
Drug: astemizole 10
RxNorm normalized name: astemizole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: astemizole 10 mg once a day
Trial: 24171300
Drug: Sertaconazole 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertaconazole 2% cream, applied twice a day for 4 weeks
Trial: 24881281
Drug: Hydrocortisone 1%
RxNorm normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 1% cream, applied twice a day for 4 weeks
Trial: 21214918
Drug: Patient-centred, structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centred, structured pharmaceutical care process
Trial: 17315118
Drug: Telemetric body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemetric body weight monitoring (TBWM) with weekly reports of weight changes and alarms for IWG greater than 0.75 kg/d
Trial: 15285314
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine + fentanyl combination
Trial: 9055897
Drug: 30% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% glucose solution (1 ml)
Trial: 8436151
Drug: Nicorandil (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (various doses)
Trial: 30454669
Drug: Financial incentives
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Financial incentives up to $60 per participant and nicotine patches
Trial: 30454669
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus nicotine patches
Trial: 20231198
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) 3 mg/kg q8w
Trial: 20231198
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) 3 mg/kg q8w, with dose escalation to 5 mg/kg if target not met
Trial: 18779287
Drug: 1800 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg/d EPA+DHA
Trial: 18779287
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d EPA+DHA
Trial: 12001120
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (cisplatin and 5-fluorouracil) followed by radiotherapy
Trial: 10494606
Drug: IFN alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN alpha 2a (6 MU, thrice weekly)
Trial: 10494606
Drug: Ribavirin (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (14 mg/kg per day) in combination with IFN alpha 2a
Trial: 8967579
Drug: Antibiotic bonded
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic bonded catheters (vancomycin 1 g in 10 ml of water)
Trial: 31369771
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of bivalent HPV vaccine (0.1 to 0.3 mL) at 2-week intervals until complete clearance or for a maximum of 6 sessions
Trial: 31369771
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of bivalent HPV vaccine at 0, 1, and 6 months or until complete clearance of warts
Trial: 31839083
Drug: Ultrasound-guided ESPB
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided ESPB with 20 ml of 0.5% ropivacaine
Trial: 31839083
Drug: Wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration with 20 ml of 0.5% ropivacaine
Trial: 26166532
Drug: N2O inhalation
RxNorm normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N2O inhalation (35%-50%)
Trial: 26166532
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.50-0.75 mg/kg)
Trial: 23334103
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OXT) - repeated administration prior to encoding and retrieval
Trial: 23334103
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OXT) - single administration prior to encoding
Trial: 21851876
Drug: Carperitide infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carperitide infusion (hANP)
Trial: 19318693
Drug: CP-690,550 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 15 mg twice daily
Trial: 15458808
Drug: Glucose (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (25 g glucose drink)
Trial: 11270304
Drug: Terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 1% solution applied twice daily for 1 week
Trial: 11270304
Drug: Terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 1% solution applied once daily for 1 week
Trial: 2434546
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control applied twice daily for 1 week
Trial: 11270304
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control applied once daily for 1 week
Trial: 9639372
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of reduced glutathione (GSH, 50 mg/min)
Trial: 2760247
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 10 mM flurbiprofen solution in buffered preservative
Trial: 2760247
Drug: Buffered preservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered preservative solution (control)
Trial: 1000999
Drug: Dothiepin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dothiepin (75 mg once daily)
Trial: 1000999
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 mg 3-times a day)
Trial: 19906348
Drug: Aripiprazole 10
RxNorm normalized name: aripiprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 10 mg/d
Trial: 23212806
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily (intensive therapy)
Trial: 23212806
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg (standard therapy)
Trial: 23212806
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (intensive and standard therapy)
Trial: 23212806
Drug: Urinary albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary albumin concentration >300 mcg/ml
Trial: 21291377
Drug: Topical biphasic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical biphasic IFN α (1 MU/dose) applied twice daily for two weeks
Trial: 21291377
Drug: Topical biphasic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical biphasic IFN α formulations (5, 15, and 40 MU/g) applied in a patch on healthy volunteers' upper inner arm
Trial: 16911680
Drug: rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 10 mg q.d. for 6 weeks
Trial: 16911680
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg q.d. for 6 weeks
Trial: 6702817
Drug: Plasma glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma glucose one hour post oral glucose load
Trial: 6702817
Drug: Plasma glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma glucose two hour post oral glucose load
Trial: 6702817
Drug: Full three-sample
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full three-sample oral glucose tolerance test
Trial: 30813800
Drug: 24-hour infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour infusion ACB
Trial: 30813800
Drug: 48-hour infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48-hour infusion ACB
Trial: 28118938
Drug: PIKA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIKA vaccine accelerated regimen
Trial: 28118938
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine classic regimen
Trial: 15471379
Drug: Monthly intravenous
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly intravenous corticosteroids (1 g) during the six months postpartum
Trial: 15471379
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment after delivery
Trial: 7891203
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of beta-carotene preparation (30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene)
Trial: 2851172
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + cis‐DDP 15 mg/m2 IV weekly
Trial: 20128578
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone acetate 1% four times daily for 1 week
Trial: 20128578
Drug: No steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No steroid therapy
Trial: 9892280
Drug: Ivermectin (annual,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (annual, 3-monthly, and 6-monthly doses)
Trial: 8062508
Drug: Brain natriuretic
RxNorm normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain natriuretic peptide infusion at 0.4 pmol min‐1 kg‐1, doubling every 15 min to 6.4 pmol min‐1 kg‐1 for 30 min
Trial: 8062508
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide infusion at 0.75 pmol min‐1 kg‐1 for 3 h
Trial: 8062508
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atrial natriuretic peptide and brain natriuretic peptide infusion for 3 h
Trial: 8062508
Drug: Control infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control infusion (vehicle)
Trial: 30442868
Drug: ACTH (repository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH (repository corticotropin injection) 80 U/1.73 m2 administered twice weekly for 6 months, followed by 40 U/1.73 m2 administered twice weekly for 6 months
Trial: 30442868
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no relapse-preventing treatment)
Trial: 30442868
Drug: ACTH treatment
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH treatment after dose reduction
Trial: 16087057
Drug: ACTH treatment
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH treatment
Trial: 27789470
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (PC, GC, PLDC)
Trial: 23153742
Drug: Usual medical
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual medical care and treatment
Trial: 23275387
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg prednisolone daily (P-group)
Trial: 16293793
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg daily aspirin
Trial: 11430539
Drug: 0.3 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 U/kg daily of human recombinant GH
Trial: 11430539
Drug: Standard ICU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ICU treatment
Trial: 9806703
Drug: Albuterol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (2 puffs via metered dose inhaler)
Trial: 9806703
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 puffs via metered dose inhaler)
Trial: 9806703
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (albuterol-treated and untreated)
Trial: 8311204
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion anaesthesia (induced with propofol 2.5 mg.kg‐1 and maintained with propofol 12 mg.kg‐1 x h‐1 and 30% O2 in air)
Trial: 8311204
Drug: Thiopentone anaesthesia
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone anaesthesia (induced with thiopentone 4 mg.kg‐1 and maintained with 70% N2O in O2)
Trial: 2898636
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg transdermal glyceryl trinitrate (GTN)
Trial: 31194712
Drug: MF59-adjuvanted, cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted, cell culture-derived H5N1 vaccine (7.5 μg full dose)
Trial: 31194712
Drug: MF59-adjuvanted, cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted, cell culture-derived H5N1 vaccine (3.75 μg half dose)
Trial: 28509725
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg/day
Trial: 19894369
Drug: Topical vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vitamin K oxide gel
Trial: 2434976
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of 0.5% tetracaine with 5% Trendelenburg position for 45 s